Cargando…

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex

The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Sravya, Maddukuri, Deveswaran, Rajamanickam, Bharath, Srinivasan, Basavaraj, Basappa Veerbadraiah, Madhavan, Varadharajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590806/
https://www.ncbi.nlm.nih.gov/pubmed/26555987
http://dx.doi.org/10.1155/2013/583536
_version_ 1782392983660789760
author Sravya, Maddukuri
Deveswaran, Rajamanickam
Bharath, Srinivasan
Basavaraj, Basappa Veerbadraiah
Madhavan, Varadharajan
author_facet Sravya, Maddukuri
Deveswaran, Rajamanickam
Bharath, Srinivasan
Basavaraj, Basappa Veerbadraiah
Madhavan, Varadharajan
author_sort Sravya, Maddukuri
collection PubMed
description The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1 : 5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs.
format Online
Article
Text
id pubmed-4590806
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45908062015-10-13 Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex Sravya, Maddukuri Deveswaran, Rajamanickam Bharath, Srinivasan Basavaraj, Basappa Veerbadraiah Madhavan, Varadharajan J Pharm (Cairo) Research Article The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1 : 5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs. Hindawi Publishing Corporation 2013 2013-09-24 /pmc/articles/PMC4590806/ /pubmed/26555987 http://dx.doi.org/10.1155/2013/583536 Text en Copyright © 2013 Maddukuri Sravya et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sravya, Maddukuri
Deveswaran, Rajamanickam
Bharath, Srinivasan
Basavaraj, Basappa Veerbadraiah
Madhavan, Varadharajan
Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title_full Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title_fullStr Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title_full_unstemmed Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title_short Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
title_sort development of orodispersible tablets of candesartan cilexetil-β-cyclodextrin complex
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590806/
https://www.ncbi.nlm.nih.gov/pubmed/26555987
http://dx.doi.org/10.1155/2013/583536
work_keys_str_mv AT sravyamaddukuri developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex
AT deveswaranrajamanickam developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex
AT bharathsrinivasan developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex
AT basavarajbasappaveerbadraiah developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex
AT madhavanvaradharajan developmentoforodispersibletabletsofcandesartancilexetilbcyclodextrincomplex